Table 3 Results of Begg’s test and Egger’s test. Note: *p < 0.05, **p < 0.01, △p > 0.05. ICU: intensive care unit
From: Rheumatoid arthritis and COVID-19 outcomes: a systematic review and Meta-analysis
NO. of included studies | Begg’s test | Egger’s test | ||||
|---|---|---|---|---|---|---|
z | p | t | p | |||
Prevalence of COVID-19 in RA patients | 36 | 3.43 | 0.001** | 0.38 | 0.705â–³ | |
The risk of COVID-19 in RA patients | 12 | 0.21 | 0.837â–³ | -0.05 | 0.962â–³ | |
Severe COVID-19 in RA patients | 11 | 0.31 | 0.755â–³ | 2.97 | 0.016* | |
The risk of severe COVID-19 in RA patients | 8 | -0.12 | 1.000â–³ | 0.02 | 0.985â–³ | |
COVID-19-related hospitalization in RA patients | 14 | 0.44 | 0.661â–³ | 0.97 | 0.353â–³ | |
The risk of COVID-19-related hospitalization in RA patients | 13 | 1.40 | 0.161â–³ | 0.24 | 0.818â–³ | |
COVID-19-related admission to ICU in RA patients | 7 | 0.00 | 1.000â–³ | 1.76 | 0.139â–³ | |
The risk of COVID-19-related admission to ICU in RA patients | 5 | 0.73 | 0.462â–³ | 1.39 | 0.258â–³ | |
COVID-19 mortality in RA patients | 16 | 0.77 | 0.444â–³ | 1.63 | 0.125â–³ | |
The risk of dying from COVID-19 in RA patients | 13 | -0.06 | 1.000â–³ | 1.12 | 0.288â–³ | |